Do analysts rate PLUR or IBIO?

iBio has a consensus target price of $5.00, suggesting a potential upside of 197.62%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 iBio 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13

Which has preferable earnings & valuation, PLUR or IBIO?

iBio has lower revenue, but higher earnings than Pluri. iBio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.34M 17.03 -$22.58M -$4.53 N/A iBio $300K 278.20 -$18.38M -$0.58 N/A

Is PLUR or IBIO more profitable?

iBio has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% iBio N/A -53.86% -46.48%

Does the media refer more to PLUR or IBIO?

In the previous week, iBio had 3 more articles in the media than Pluri. MarketBeat recorded 4 mentions for iBio and 1 mentions for Pluri. iBio's average media sentiment score of 0.16 beat Pluri's score of 0.00 indicating that iBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral iBio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PLUR or JATT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, PLUR or JATT?

JATT Acquisition has lower revenue, but higher earnings than Pluri. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.34M 17.03 -$22.58M -$4.53 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Is PLUR or JATT more profitable?

JATT Acquisition has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% JATT Acquisition N/A -49.58% 2.84%

Does the media prefer PLUR or JATT?

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral JATT Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CRDF or PLUR?

Cardiff Oncology presently has a consensus target price of $9.80, indicating a potential upside of 671.65%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Cardiff Oncology is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, CRDF or PLUR?

Pluri has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiff Oncology $590K 147.17 -$45.85M -$0.67 N/A Pluri $1.34M 17.03 -$22.58M -$4.53 N/A

Is CRDF or PLUR more profitable?

Pluri has a net margin of -2,162.08% compared to Cardiff Oncology's net margin of -8,527.43%. Pluri's return on equity of 0.00% beat Cardiff Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Cardiff Oncology -8,527.43% -95.51% -71.47% Pluri -2,162.08% N/A -106.59%

Do analysts recommend PLUR or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend PLUR or AIFC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, PLUR or AIFC?

Pluri has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.34M 17.03 -$22.58M -$4.53 N/A ALT5 Sigma $24.70M 3.40 -$344.51M N/A N/A

Is PLUR or AIFC more profitable?

Pluri has a net margin of -2,162.08% compared to ALT5 Sigma's net margin of -2,483.94%. Pluri's return on equity of 0.00% beat ALT5 Sigma's return on equity. Company Net Margins Return on Equity Return on Assets Pluri -2,162.08% N/A -106.59% ALT5 Sigma -2,483.94% -68.25% -62.43%

Does the media refer more to PLUR or AIFC?

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.00 equaled ALT5 Sigma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pluri (PLUR) Competitors

$2.12 +0.01 (+0.24%)

Closing price 07/2/2026 03:54 PM Eastern

Extended Trading

$2.09 -0.03 (-1.18%)

As of 07/2/2026 04:58 PM Eastern

Compare

PLUR vs. IBIO, JATT, CRDF, TELO, and AIFC

Should you buy Pluri stock or one of its competitors? MarketBeat compares Pluri with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pluri include iBio (IBIO), JATT Acquisition (JATT), Cardiff Oncology (CRDF), Telomir Pharmaceuticals (TELO), and ALT5 Sigma (AIFC). These companies are all part of the "pharmaceutical products" industry.

How does Pluri compare to iBio?

Pluri (NASDAQ:PLUR) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

iBio has lower revenue, but higher earnings than Pluri. iBio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	17.03	-$22.58M	-$4.53	N/A
iBio	$300K	278.20	-$18.38M	-$0.58	N/A

iBio has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
iBio	N/A	-53.86%	-46.48%

In the previous week, iBio had 3 more articles in the media than Pluri. MarketBeat recorded 4 mentions for iBio and 1 mentions for Pluri. iBio's average media sentiment score of 0.16 beat Pluri's score of 0.00 indicating that iBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
iBio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio has a consensus target price of $5.00, suggesting a potential upside of 197.62%. Given iBio's stronger consensus rating and higher probable upside, analysts clearly believe iBio is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Pluri has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, iBio has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

16.6% of Pluri shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

iBio beats Pluri on 12 of the 17 factors compared between the two stocks.

How does Pluri compare to JATT Acquisition?

Pluri (NASDAQ:PLUR) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

JATT Acquisition has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
JATT Acquisition	N/A	-49.58%	2.84%

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

JATT Acquisition has lower revenue, but higher earnings than Pluri.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	17.03	-$22.58M	-$4.53	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

16.6% of Pluri shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Pluri and JATT Acquisition tied by winning 4 of the 8 factors compared between the two stocks.

How does Pluri compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Cardiff Oncology has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, Pluri has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market.

Pluri has a net margin of -2,162.08% compared to Cardiff Oncology's net margin of -8,527.43%. Pluri's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Pluri	-2,162.08%	N/A	-106.59%

In the previous week, Pluri had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.00 equaled Pluri'saverage media sentiment score.

Company	Overall Sentiment
Cardiff Oncology	Neutral
Pluri	Neutral

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 8.5% of Cardiff Oncology shares are held by company insiders. Comparatively, 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pluri has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	147.17	-$45.85M	-$0.67	N/A
Pluri	$1.34M	17.03	-$22.58M	-$4.53	N/A

Cardiff Oncology presently has a consensus target price of $9.80, indicating a potential upside of 671.65%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Cardiff Oncology is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Pluri beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks.

How does Pluri compare to Telomir Pharmaceuticals?

Pluri (NASDAQ:PLUR) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

16.6% of Pluri shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pluri has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Pluri had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Telomir Pharmaceuticals. Pluri's average media sentiment score of 0.00 equaled Telomir Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Pluri	Neutral
Telomir Pharmaceuticals	Neutral

Telomir Pharmaceuticals has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Telomir Pharmaceuticals has lower revenue, but higher earnings than Pluri. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	17.03	-$22.58M	-$4.53	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Summary

Pluri beats Telomir Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Pluri compare to ALT5 Sigma?

Pluri (NASDAQ:PLUR) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Pluri and Pluri both had 1 articles in the media. Pluri's average media sentiment score of 0.00 equaled ALT5 Sigma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pluri has a net margin of -2,162.08% compared to ALT5 Sigma's net margin of -2,483.94%. Pluri's return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Pluri has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34M	17.03	-$22.58M	-$4.53	N/A
ALT5 Sigma	$24.70M	3.40	-$344.51M	N/A	N/A

Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.6% of Pluri shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 43.2% of Pluri shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Pluri beats ALT5 Sigma on 6 of the 9 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLUR vs. The Competition

Export

Metric	Pluri	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$22.77M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.47	21.61	28.02	24.70
Price / Sales	17.03	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-19.23	8.66	10.96	6.46
Net Income	-$22.58M	$23.81M	$3.57B	$337.01M
7 Day Performance	-4.51%	3.39%	2.12%	1.69%
1 Month Performance	-11.13%	10.81%	5.25%	3.81%
1 Year Performance	-63.22%	62.61%	33.29%	23.90%

Pluri Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLUR Pluri	0.5807 of 5 stars	$2.12 +0.2%	N/A	-63.2%	$22.77M	$1.34M	N/A	150	News Coverage
IBIO iBio	3.3721 of 5 stars	$1.83 +4.3%	$5.00 +174.0%	N/A	$91.16M	$400K	N/A	100	News Coverage Positive News Analyst Forecast High Trading Volume
JATT JATT Acquisition	N/A	$11.34 -3.5%	N/A	+950.0%	$91.00M	N/A	N/A	3	Gap Down
CRDF Cardiff Oncology	3.304 of 5 stars	$1.28 -1.9%	$9.80 +668.6%	-65.3%	$87.86M	$590K	N/A	20
TELO Telomir Pharmaceuticals	0.1491 of 5 stars	$1.28 -0.4%	N/A	+7.6%	$87.69M	N/A	N/A	1	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLUR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pluri (PLUR) Competitors

PLUR vs. IBIO, JATT, CRDF, TELO, and AIFC

How does Pluri compare to iBio?

Summary

How does Pluri compare to JATT Acquisition?

Summary

How does Pluri compare to Cardiff Oncology?

Summary

How does Pluri compare to Telomir Pharmaceuticals?

Summary

How does Pluri compare to ALT5 Sigma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pluri (PLUR) Competitors

PLUR vs. IBIO, JATT, CRDF, TELO, and AIFC

How does Pluri compare to iBio?

Which has preferable earnings & valuation, PLUR or IBIO?

Is PLUR or IBIO more profitable?

Does the media refer more to PLUR or IBIO?

Do analysts rate PLUR or IBIO?

Which has more volatility and risk, PLUR or IBIO?

Do insiders and institutionals hold more shares of PLUR or IBIO?

Summary

How does Pluri compare to JATT Acquisition?

Do analysts recommend PLUR or JATT?

Is PLUR or JATT more profitable?

Does the media prefer PLUR or JATT?

Which has stronger earnings & valuation, PLUR or JATT?

Do insiders and institutionals believe in PLUR or JATT?

Summary

How does Pluri compare to Cardiff Oncology?

Which has more risk and volatility, CRDF or PLUR?

Is CRDF or PLUR more profitable?

Does the media favor CRDF or PLUR?

Do insiders & institutionals hold more shares of CRDF or PLUR?

Which has stronger valuation and earnings, CRDF or PLUR?

Do analysts prefer CRDF or PLUR?

Summary

How does Pluri compare to Telomir Pharmaceuticals?

Do institutionals and insiders believe in PLUR or TELO?

Which has more volatility & risk, PLUR or TELO?

Do analysts recommend PLUR or TELO?

Does the media refer more to PLUR or TELO?

Is PLUR or TELO more profitable?

Which has higher earnings and valuation, PLUR or TELO?

Summary

How does Pluri compare to ALT5 Sigma?

Does the media refer more to PLUR or AIFC?

Is PLUR or AIFC more profitable?

Which has preferable valuation and earnings, PLUR or AIFC?

Which has more volatility and risk, PLUR or AIFC?

Do analysts recommend PLUR or AIFC?

Do institutionals & insiders believe in PLUR or AIFC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLUR vs. The Competition

Pluri Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools